Alofanib (RPT835)是一种新型的、选择性FGFR2变构抑制剂，在KATO III细胞中对FGF2诱导的FRS2α磷酸化具有显著的抑制效果，IC50小于10 nM。在细胞中，它对依赖于FGF2的FGFR1和FGFR3磷酸化水平没有直接作用，对FGF2-FGFR2的结合没有影响。 Information Alofanib (RPT835) Alofanib (RPT835) is a novel selective allosteric inhibitor of FGFR2 and has a dramatic inhibitory effect with IC50 Targets FGFR2 (Cell-free assay) In vitro Alofanib induces mainly apoptosis with cleavage of caspase 3, PARP and Bcl-2 in SKOV3 cell line. Cytotoxic effect of compound on ovarian cancer cells is low. Alofanib inhibits phosphorylation of FRS2α with the IC50 values of 7 and 9 nmol/l in cancer cells expressing different FGFR2 isoforms. In a panel of four cell lines representing several tumour types (triple-negative breast cancer,melanoma, and ovarian cancer), alofanib inhibits FGF-mediated proliferation with 50% growth inhibition (GI50) values of 16-370 nmol/l. Alofanib dose dependently inhibits the proliferation and migration of human and mouse endothelial cells (GI50: 11-58 nmol/l) compared with brivanib and bevacizumab. In vivo Intravenous alofanib significantly in dose-dependent manner potentiated the efficiency of the combination of paclitaxel and carboplatin. Alofanib suppresses angiogenesis in ovarian cancer mouse model. In a FGFR-driven human tumour xenograft model, oral administration of alofanib is well tolerated and results in potent antitumour activity. Cell Research(from reference) Cell lines：SKOV3 cells Concentrations：0-1 μM Incubation Time：72 h